Comparative Pharmacology
Head-to-head clinical analysis: GABLOFEN versus ORPHENADRINE CITRATE ASPIRIN AND CAFFEINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GABLOFEN versus ORPHENADRINE CITRATE ASPIRIN AND CAFFEINE.
GABLOFEN vs ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABLOFEN (baclofen) is a GABA-B receptor agonist that reduces spinal reflex transmission and inhibits excitatory neurotransmitter release.
Orphenadrine citrate is a centrally acting muscle relaxant with anticholinergic properties; aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis; caffeine is a central nervous system stimulant that antagonizes adenosine receptors.
10 mg orally three times daily, may increase by 10 mg/day every 3 days to a maximum of 80 mg/day (20 mg four times daily).
1-2 tablets (orphenadrine citrate 50 mg, aspirin 770 mg, caffeine 60 mg per tablet) orally every 8-12 hours as needed; maximum 4 tablets per day.
None Documented
None Documented
Terminal half-life 5-7 hours; clinically relevant for dosing interval of every 6-8 hours.
Orphenadrine: ~14 hours (range 12-16 h); Aspirin: 2-3 h for low doses, 15-30 h for high/anti-inflammatory doses due to saturable metabolism; Caffeine: 3-6 h in adults, prolonged in liver disease.
Renal: 70-80% unchanged; biliary/fecal: <5% as metabolites. Total clearance 2.5-3.0 L/h.
Orphenadrine: ~60% renal (metabolites, <8% unchanged), ~20% biliary/fecal; Aspirin: ~80-100% renal (salicylates, dose-dependent; alkaline urine increases excretion); Caffeine: ~1-3% renal (unchanged), main metabolites renal.
Category C
Category A/B
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant